Fragile sites are preferential targets for integrations of MLV vectors in gene therapy

A. C. Bester, M. Schwartz, M. Schmidt, A. Garrigue, S. Hacein-Bey-Abina, M. Cavazzana-Calvo, N. Ben-Porat, C. Von Kalle, A. Fischer, B. Kerem*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Fingerprint

Dive into the research topics of 'Fragile sites are preferential targets for integrations of MLV vectors in gene therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences